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Abstract
Objective: To determine whether neurophysiological mechanisms indicating
cortical excitability, long-term potentiation (LTP)-like plasticity, GABAergic
and glutamatergic function are altered in patients with anti-N-methyl-D-aspar-
tate receptor (NMDAR) encephalitis and whether they can be helpful as mark-
ers of diagnostic assessment, disease progression, and potentially therapy
response. Methods: Neurophysiological characterizations of patients with
NMDAR encephalitis (n = 34, mean age: 28  11 years; 30 females) and age/
gender-matched healthy controls (n = 27, 28.5  10 years; 25 females) were
performed using transcranial magnetic stimulation-derived protocols including
resting motor threshold, recruitment curve, intracortical facilitation, short intra-
cortical inhibition, and cortical silent period. Paired associative stimulation
(PAS) was applied to assess LTP-like mechanisms which are mediated through
NMDAR. Moreover, resting state functional connectivity was determined using
functional magnetic resonance imaging. Results: PAS-induced plasticity differed
significantly between groups (P = 0.0056). Cortical excitability, as assessed via
motor-evoked potentials after PAS, decreased in patients, whereas it increased
in controls indicating malfunctioning of NMDAR in encephalitis patients.
Lower PAS-induced plasticity significantly correlated with the modified Rankin
Scale (mRS) (r = 0.41; P = 0.0031) and was correlated with lower functional
connectivity within the motor network in NMDAR encephalitis patients
(P < 0.001, uncorrected). Other neurophysiological parameters were not signifi-
cantly different between groups. Follow-up assessments were available in six
patients and demonstrated parallel improvement of PAS-induced plasticity and
mRS. Interpretation: Assessment of PAS-induced plasticity may help to deter-
mine NMDAR dysfunction and disease severity in NMDAR encephalitis, and
might even aid as a sensitive, noninvasive, and well-tolerated “electrophysiologi-
cal biomarker” to monitor therapy response in the future. Clinical Trial
Registration: ClinicalTrials.gov: Identifier: NCT01865578
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Introduction
Anti-N-methyl-D-aspartate receptor (NMDAR) encephali-
tis is the most common antibody-mediated autoimmune
encephalitis following a characteristic clinical course
including psychiatric features, amnesia, epileptic seizures,
and abnormal movements.1 Autoantibodies against the
NR1 subunit of the NMDAR are found in serum and
cerebrospinal fluid (CSF).2 They interfere with synaptic
function by specific downregulation of neuronal mem-
brane NMDAR.3 Antibody detection guides early diagnos-
tics, and most patients benefit profoundly from rapid
initiation of immunotherapy. However, understanding of
the neurophysiological changes underlying altered clinical
and cognitive function in the human brain remains
incomplete, and lack of disease markers for prognosis and
treatment monitoring often delays appropriate therapy.
Both better understanding of neurophysiological under-
pinnings and noninvasive, objective, and widely available
methods for determination of clinical severity are urgently
needed.
Transcranial magnetic stimulation (TMS) is a noninva-
sive technique to assess human cortical neurophysiology
in health and disease. Most commonly used TMS param-
eters are resting motor threshold (RMT), recruitment
curve (RC), intracortical facilitation (ICF), short intracor-
tical inhibition (SICI), and cortical silent period (CSP).
They allow assessment of different neurotransmitter sys-
tems including predominant glutamatergic (ICF and
paired associative stimulation [PAS]), GABA(A)ergic
(SICI, motor-evoked potentials [MEP], and CSP with low
intensity), and GABA(B)ergic (SICI and CSP with high
intensity) functions, confirmed in pharmacological stud-
ies.4 For example, cortical excitability and the paradigms
of SICI and ICF were conversely changed by the NMDAR
antagonist memantine.4,5 However, no TMS parameter is
solely mediated by a single neurotransmitter but rather by
a combination of several neurotransmitters to a different
degree.
One of the main factors underlying learning and mem-
ory formation at the cellular level is long-term potentia-
tion (LTP).6,7 In humans, LTP-like cortical plasticity can
be assessed using peripheral electric stimulation and sub-
sequent TMS. This so-called PAS8 is now a widely used
protocol to noninvasively investigate rapid-onset cortical
plasticity in healthy subjects and neurological patients.9–12
Importantly, it has been shown to predominantly reflect
NMDAR function,8,13,14 whereas MEP and motor thresh-
old (MT) are relatively independent from NMDAR func-
tion.4,8,13,15–17
Thus, PAS is an exciting candidate for assessing the
underlying neurophysiological dysfunction and related
clinical disability in NMDAR encephalitis. In the present
study, we therefore aimed to determine (1) whether there
are differences in PAS between NMDAR encephalitis
patients and healthy controls, (2) whether other TMS-
derived neurophysiological parameters which are not
mediated through NMDAR are altered, (3) whether neu-
rophysiological parameters change throughout the course
of disease, and (4) whether neurophysiological parameters
correlate with other markers of disease activity such as a
disease severity questionnaire (modified Rankin Scale,
mRS) and resting state functional connectivity.
Material and Methods
Experimental design and subjects
In this parallel design trial, 34 patients (mean age
28.03  10.85 years; 30 females, range: 18–68 years) with
NMDAR encephalitis and 27 age- and sex-matched healthy
controls (mean age 28.48  9.76 years; 25 females, range:
21–60 years) were enrolled. Six encephalitis patients
received repeated measurement for follow-up analyses. Par-
ticipants underwent TMS assessments reported in accor-
dance to the checklist for assessing methodological quality
for TMS studies18 (Table S1). PAS protocol was defined as
primary outcome. Secondary outcomes were other TMS
measurements such as MEP, CSP, ICF, and SICI as well as
exploratory correlation analyses of TMS-derived neuro-
physiological parameters with clinician-based rating of dis-
ease activity (mRS) and functional magnetic resonance
imaging–based resting state functional connectivity.
Both groups were screened for contraindication for
TMS assessments (see below), handedness indexed by
Edinburgh Handedness Inventory,19 and the mRS, which
runs from 0 to 6 scoring from complete health to severe
symptoms to death.20 Despite limited capability to detect
subtle clinical changes, the mRS was used in this study to
allow comparability with previous studies in NMDAR
encephalitis.1
Eligibility was defined as follows: patients and controls
– (1) age above 18 years; (2) no contraindications for
TMS such as a head injury or surgery, implanted medical
devices, and any metal in the head; (3) no seizure in the
last 6 months. Only controls – (4) no centrally active
medication and (5) no medical, psychiatric, or neurologi-
cal disorders. Only patients – (6) diagnosis of NMDAR
encephalitis based on the characteristic clinical picture
with signs of encephalitis (epileptic seizures, reduced
levels of consciousness, and cognitive or mood changes),
exclusion of alternative disorders (in particular viral
causes), evidence of brain inflammation (MRI abnormali-
ties, CSF inflammation, or positive biopsy/autopsy), and
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CSF IgG antibodies against the NMDAR at the time of
diagnosis.21,22
The study was approved by the Charite University
Hospital Institutional Review Board. All participants gave
their written informed consent. Patients were recruited
from the Department of Neurology of Charite University
Hospital and the Charite outpatient Center for Autoim-
mune Encephalitis and Paraneoplastic Neurological Syn-
dromes. The trial was registered at ClinicalTrials.gov
(identifier: NCT01865578).
Measurement of cortical excitability via TMS
Measurements were performed using a Bistim2 stimulator
and a figure-of-eight coil with 140 mm diameter (Mag-
stim Company LTDA, Whitland, Dyfed, UK). Participants
were seated in a comfortable chair. To record MEP, Ag/
AgCl electrodes (ADinstruments, Colorado Springs, CO,
USA) were placed over the first dorsal interosseous mus-
cle (FDI), and a ground electrode was placed over the
subjects’ forearm. Recordings were processed through Sig-
nal 4.05 software (Cambridge Electronic Design, Cam-
bridge, UK) with a bandpass filter of 100 Hz to 10 kHz.
Offline analyses were made with the Signal 4.05 software.
TMS was applied over the hemisphere contralateral to the
dominant hand. Initially, head measurements were taken
to identify the location of the motor cortex (using the
nasion, inion, and vertex as reference, then calculating
individual 20% of the distance between both tragus spots
to identify M1). Then, the TMS coil was held tangentially
over M1 with an angle of 45° with respect to the sagittal
line of the head. The exact hotspot was determined by
eliciting the most stable and highest MEP amplitudes over
the FDI. The hotspot was marked with a pen on each of
the subjects’ heads to secure coil location and stability.
Between each TMS pulse we set an interval of approxi-
mately 10 sec to avoid habituation.
First, RMT was assessed by using the lowest stimulator
output at which three of the five trails had minimum
amplitude of 50 lV.23,24 This methodology results (to-
gether with the relatively young age of our cohort) in
lower RMT than in other published studies where the
stimulator output is set to result in 100 lV amplitudes.
For eliciting MEP, the intensity of 130% of the individual
RMT was chosen. This normalization helps to consider
the well-known interindividual variances in RMT. RC was
assessed using the intensities of 130%, 140%, and 150%
of the individual RMT.25 For the statistical analyses, we
calculated the mean of 10 MEP per intensity. With these
MEPs of different intensities, we calculated the ratios
(130/150, and 130/140 and 140/150 for all subjects) and
determined the RC.
CSP was assessed using stimulator output intensity at
110% and 140% of the individual RMT.26 During CSP
measurement, patients had to perform isometric volun-
tary muscle contraction with approximately 10–20% of
maximal force controlled visually via EMG. For data anal-
yses, relative duration (duration of the beginning of the
last MEP until the beginning of the next MEP) of the
silent period was collected of 10 CSP. The ratio of 110/
140 was calculated as it reflects the individual change
best. Therefore, comparing results of patients and controls
with this ratio, the pure differences between those groups
were most robust. These single-pulse measurements took
approximately 10–15 min.
Moreover, paired-pulse stimulation was applied using
SICI and ICF.27,28 SICI was performed using an interstimu-
lus interval (ISI) of 3 msec and ICF with an ISI of 10 msec.
For both paired-pulse measures, the first (conditioning)
stimulus was set to 70% of the individual MT, and the sec-
ond (test) stimulus was set to the individual MEP intensity
(130% of MT). Ten recordings of each TMS assessment
protocol were randomly elicited (mixed with single-pulse
test MEP). Offline analyses included measures of peak-to-
peak amplitude and the integral of all MEPs. Paired-pulse
measurements took approximately 7 min.
Paired associative stimulation
For evaluation of NMDAR-specific function, the PAS
protocol was applied, as none of the single-pulse TMS
parameter has a similarly strong linkage to NMDAR func-
tion. Before and immediately after the PAS protocol, 10
MEP at individual intensity (130% of RMT) were applied.
Furthermore, 15 min after the protocol, 10 MEP were
performed for follow-up analyses. As described before,8,10
we used paired stimulation of the ulnar nerve (electrical
stimulation with 300% of individual sensory threshold)
and the hotspot of the ipsilateral FDI over the motor cor-
tex. The interstimulus interval was set at 25 msec, which
has been proven to be robust for inducing increased cor-
tical excitability.8 A total of 131 paired pulses were
administered. In order to secure an equal state of atten-
tion during PAS protocol, participants were instructed to
stay awake, voluntarily relax the tested hand, and to
count the number of electrical ulnar nerve stimulations.
Resting state functional connectivity
Resting state functional connectivity data acquisition and
analysis were performed as described previously in
NMDAR encephalitis patients.29 Briefly, an echo-planar
imaging sequence (voxel size 3.4 mm isotropic,
TR = 2250 msec, TE = 30 msec, 260 volumes) and a
ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 103
M. S. Volz et al. Cortical Plasticity in NMDAR Encephalitis
T
a
b
le
1
.
B
as
el
in
e
ch
ar
ac
te
ri
st
ic
s
o
f
al
l
p
at
ie
n
ts
an
d
h
ea
lt
h
y
co
n
tr
o
ls
.
Pa
ti
en
ts
G
en
d
er
A
g
e
(y
ea
rs
)
D
is
ea
se
d
u
ra
ti
o
n
(m
o
n
th
s)
H
an
d
ed
n
es
s
St
im
u
la
te
d
h
em
is
p
h
er
e
m
R
S
IC
U
tr
ea
tm
en
t
Pa
st
im
m
u
n
o
su
p
p
re
ss
io
n
M
ed
ic
at
io
n
at
st
im
u
la
ti
o
n
N
M
D
A
R
ab
ti
te
r
at
TM
S
m
ea
su
re
m
en
t
C
en
tr
al
ly
ac
ti
ve
N
o
n
ce
n
tr
al
ly
ac
ti
ve
C
SF
Se
ru
m
1
Fe
m
al
e
1
8
3
3
R
ig
h
t
Le
ft
1
Y
es
M
P,
IV
IG
,
PE
,
R
it
u
x,
A
za
–
–
n
.d
.
1
0
0
0
2
Fe
m
al
e
2
2
1
1
R
ig
h
t
Le
ft
1
Y
es
M
P,
PE
,
IV
IG
Le
ve
ti
ra
ce
ta
m
–
N
eg
.
N
eg
.
3
Fe
m
al
e
4
6
2
6
Le
ft
R
ig
h
t
1
N
o
M
P,
R
it
u
x,
PE
G
ab
ap
en
ti
n
–
N
eg
.
1
0
0
4
Fe
m
al
e
2
1
1
4
R
ig
h
t
Le
ft
3
Y
es
Pr
ed
,
M
M
F
–
M
M
F;
M
P
1
3
2
5
M
al
e
3
3
1
9
R
ig
h
t
Le
ft
3
Y
es
PE
,
Pr
ed
A
m
an
ta
d
in
;
Es
ci
ta
lo
p
ra
m
–
1
0
1
0
0
6
Fe
m
al
e
4
0
9
R
ig
h
t
Le
ft
2
Y
es
R
it
u
x,
Pr
ed
,
C
yc
lo
Le
ve
ti
ra
ce
ta
m
En
o
xa
p
ar
in
so
d
iu
m
N
eg
.
N
eg
.
7
Fe
m
al
e
3
2
4
3
R
ig
h
t
Le
ft
2
Y
es
Pr
ed
,
PE
,
A
za
Le
ve
ti
ra
ce
ta
m
M
M
F;
R
an
it
id
in
e;
L-
Th
yr
o
xi
n
e
N
eg
.
N
eg
.
8
Fe
m
al
e
1
8
1
0
R
ig
h
t
Le
ft
2
Y
es
M
P,
IV
IG
,
PE
Le
ve
ti
ra
ce
ta
m
;
V
al
p
ro
ic
ac
id
;
Q
u
et
ia
p
in
e
Es
o
m
ep
ra
zo
le
;
Pr
ed
3
1
0
9
Fe
m
al
e
3
1
7
2
R
ig
h
t
Le
ft
2
Y
es
M
P,
IA
,
C
yc
lo
C
lo
n
az
ep
am
;
Ph
en
o
b
ar
b
it
al
;
Le
ve
ti
ra
ce
ta
m
–
N
eg
.
N
eg
.
1
0
Fe
m
al
e
2
6
4
6
R
ig
h
t
Le
ft
1
N
o
Pr
ed
–
–
N
eg
.
N
eg
.
1
1
Fe
m
al
e
2
3
4
4
Le
ft
R
ig
h
t
1
Y
es
Pr
ed
,
M
M
F
–
–
3
1
0
0
1
2
Fe
m
al
e
2
5
1
8
R
ig
h
t
Le
ft
1
Y
es
R
it
u
x,
Pr
ed
,
IV
IG
,
PE
Pr
eg
ab
al
in
Pa
n
to
p
ra
zo
le
,
M
et
o
p
ro
lo
l
3
N
eg
.
1
3
Fe
m
al
e
3
7
9
R
ig
h
t
Le
ft
2
N
o
Pr
ed
–
Pr
ed
N
eg
.
N
eg
.
1
4
Fe
m
al
e
2
5
3
3
R
ig
h
t
Le
ft
2
N
o
Pr
ed
,
PE
–
–
3
N
eg
.
1
5
Fe
m
al
e
4
6
5
7
R
ig
h
t
Le
ft
1
N
o
M
P
–
–
3
2
N
eg
.
1
6
Fe
m
al
e
2
5
1
5
R
ig
h
t
Le
ft
3
Y
es
M
P,
IV
IG
,
PE
,
IA
,
R
it
u
x
Le
ve
ti
ra
ce
ta
m
;
La
co
sa
m
id
–
1
0
3
2
1
7
Fe
m
al
e
2
1
4
R
ig
h
t
Le
ft
2
Y
es
PE
,
M
P,
R
it
u
x
V
en
la
fa
xi
n
e;
V
al
p
ro
ic
ac
id
–
1
0
1
0
0
1
8
M
al
e
6
8
3
R
ig
h
t
Le
ft
3
N
o
Pr
ed
,
IV
IG
,
R
it
u
x
V
al
p
ro
ic
ac
id
R
am
ip
ri
l;
A
m
lo
d
ip
in
e;
H
yd
ro
ch
lo
ro
th
ia
zi
d
e;
Pa
n
to
p
ra
zo
le
;
Pr
ed
;
Si
ta
g
lip
ti
n
1
1
0
0
1
9
Fe
m
al
e
1
8
4
R
ig
h
t
Le
ft
2
N
o
Pr
ed
,
PE
,
R
it
u
x
La
co
sa
m
id
Pr
ed
1
0
0
1
0
2
0
Fe
m
al
e
2
2
3
5
Le
ft
R
ig
h
t
1
Y
es
Pr
ed
,
IV
IG
,
PE
,
IA
,
R
it
u
x
–
–
1
0
1
0
0
2
1
Fe
m
al
e
2
2
8
R
ig
h
t
Le
ft
3
Y
es
PE
,
IV
IG
,
R
it
u
x,
C
yc
lo
,
Pr
ed
Q
u
et
ia
p
in
e
–
3
2
3
2
0
2
2
M
al
e
3
1
8
0
R
ig
h
t
Le
ft
3
N
o
–
V
al
p
ro
ic
ac
id
M
ar
ih
u
an
a
3
1
2
3
Fe
m
al
e
1
8
5
R
ig
h
t
Le
ft
2
Y
es
Pr
ed
,
IV
IG
,
PE
,
R
it
u
x
V
al
p
ro
ic
ac
id
;
Le
ve
ti
ra
ce
ta
m
–
3
2
1
0
2
4
Fe
m
al
e
2
7
6
8
R
ig
h
t
Le
ft
1
Y
es
IV
IG
,
M
P
Le
ve
ti
ra
ce
ta
m
–
1
N
eg
.
2
5
Fe
m
al
e
2
5
3
5
R
ig
h
t
Le
ft
3
Y
es
V
al
p
ro
ic
ac
id
A
sp
ir
in
;
Fo
lin
ic
ac
id
;
M
TX
n
.d
.
1
0
(C
o
n
ti
n
u
ed
)
104 ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Cortical Plasticity in NMDAR Encephalitis M. S. Volz et al.
T
a
b
le
1
.
C
o
n
ti
n
u
ed
.
Pa
ti
en
ts
G
en
d
er
A
g
e
(y
ea
rs
)
D
is
ea
se
d
u
ra
ti
o
n
(m
o
n
th
s)
H
an
d
ed
n
es
s
St
im
u
la
te
d
h
em
is
p
h
er
e
m
R
S
IC
U
tr
ea
tm
en
t
Pa
st
im
m
u
n
o
su
p
p
re
ss
io
n
M
ed
ic
at
io
n
at
st
im
u
la
ti
o
n
N
M
D
A
R
ab
ti
te
r
at
TM
S
m
ea
su
re
m
en
t
C
en
tr
al
ly
ac
ti
ve
N
o
n
ce
n
tr
al
ly
ac
ti
ve
C
SF
Se
ru
m
M
P,
PE
,
IV
IG
,
C
yc
lo
,
R
it
u
x,
M
TX
2
6
Fe
m
al
e
3
7
4
R
ig
h
t
Le
ft
3
N
o
M
P,
IA
–
L-
Th
yr
o
xi
n
e,
C
et
ir
iz
in
e
3
1
0
0
2
7
Fe
m
al
e
1
8
4
6
R
ig
h
t
Le
ft
0
Y
es
M
P,
IV
IG
–
–
3
1
0
2
8
Fe
m
al
e
3
7
7
R
ig
h
t
Le
ft
1
N
o
Pr
ed
,
R
it
u
x,
PE
–
–
N
eg
.
1
0
0
2
9
Fe
m
al
e
1
8
1
1
R
ig
h
t
Le
ft
2
Y
es
M
P,
R
it
u
x,
PE
Le
ve
ti
ra
ce
ta
m
L-
Th
yr
o
xi
n
e
3
2
1
0
0
0
3
0
Fe
m
al
e
2
6
5
0
Le
ft
R
ig
h
t
1
Y
es
Pr
ed
,
IV
IG
–
–
n
.d
.
1
0
3
1
Fe
m
al
e
1
8
1
1
R
ig
h
t
Le
ft
1
Y
es
Pr
ed
,
IV
IG
,
R
it
u
x
Le
ve
ti
ra
ce
ta
m
L-
Th
yr
o
xi
n
e
1
0
1
0
0
3
2
M
al
e
3
8
5
R
ig
h
t
Le
ft
1
Y
es
PE
,
Pr
ed
M
ir
ta
za
p
in
e;
R
is
p
er
d
al
;
B
ip
er
id
en
;
O
xc
ar
b
az
ep
in
e;
V
al
p
ro
ic
ac
id
–
3
3
2
3
3
Fe
m
al
e
2
2
6
R
ig
h
t
Le
ft
1
Y
es
PE
,
Pr
ed
,
IV
IG
,
R
it
u
x
Q
u
et
ia
p
in
e;
To
p
ir
am
at
e
R
it
u
x;
PE
1
0
1
0
0
3
4
Fe
m
al
e
1
9
2
3
R
ig
h
t
Le
ft
1
Y
es
Pr
ed
,
IV
IG
,
PE
Se
rt
ra
lin
e
Fo
lin
ic
ac
id
;
M
TX
n
.d
.
1
0
0
H
ea
lt
h
y
co
n
tr
o
ls
1
Fe
m
al
e
2
5
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
2
Fe
m
al
e
2
6
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
3
Fe
m
al
e
3
5
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
4
Fe
m
al
e
2
5
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
5
Fe
m
al
e
2
4
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
L-
Th
yr
o
xi
n
e
N
/A
N
/A
6
M
al
e
3
5
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
7
Fe
m
al
e
5
6
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
8
Fe
m
al
e
2
3
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
9
Fe
m
al
e
2
3
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
1
0
Fe
m
al
e
2
3
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
1
1
Fe
m
al
e
2
8
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
1
2
Fe
m
al
e
2
2
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
1
3
M
al
e
6
0
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
1
4
Fe
m
al
e
2
1
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
1
5
Fe
m
al
e
2
4
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
1
6
Fe
m
al
e
2
4
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
1
7
Fe
m
al
e
2
1
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
1
8
Fe
m
al
e
2
6
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
1
9
Fe
m
al
e
2
5
N
/A
R
ig
h
t
Le
ft
0
N
/A
N
/A
–
–
N
/A
N
/A
(C
o
n
ti
n
u
ed
)
ª 2016 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 105
M. S. Volz et al. Cortical Plasticity in NMDAR Encephalitis
three-dimensional 1 mm isotropic magnetization pre-
pared rapid acquisition gradient echo sequences were
acquired on a Siemens (Erlangen, Germany) Tim Trio 3T
scanner. Analysis was performed with independent com-
ponent analysis (ICA) and dual regression using FSL
(www.fmrib.ox.ac.uk/fsl/). After preprocessing, the senso-
rimotor network was identified using temporal concatena-
tion ICA as implemented in Multivariate Exploratory
Linear Optimized Decomposition into Independent Com-
ponent (FSL MELODIC).
Statistical analyses
Statistical analyses were performed using STATA (v11.0,
College Station, TX, USA). The dependent variables were
TMS measurements. First, data were tested for normal
distribution using Skewness/Kurtosis test. If data were not
normally distributed, log transformation was performed.
Comparisons between groups (patients vs. healthy con-
trols) used the individual increase or decrease in a TMS
parameter compared to baseline MEPs (SICI/MEP; ICF/
MEP) or between MEP with different intensities (CSP:
CSP110%/CSP140%; RC: 150%/130% of MEP). With
those calculations the comparison is most precise since it
abolishes effects due to different RMT intensity and also
small shifts of the TMS coil during the course of assess-
ment.
Analysis of variance (ANOVA) was performed for TMS
analyses with the following factors: TMS measurements
(dependent variable, i.e., PAS, ICF, etc.), independent
variable of group (NMDAR encephalitis vs. controls),
time (if applicable) (i.e., MEP before and after PAS pro-
tocol), and interaction analysis of group and time. After-
ward, analyses were repeated with subgroups including
only patients without centrally active medication and
mRS > 0. Patients with mRS = 0 were excluded to distin-
guish whether differences in RMT related to functional
impairment from NMDAR encephalitis (as per definition:
0 = not functionally impaired). Furthermore, post hoc
t-tests were used to compare group differences. To corre-
late score on mRS and TMS measures, Pearson’s correla-
tion was used. All data are reported as mean  standard
error of the mean, and P-values for statistical significance
were set to P < 0.05, unless stated otherwise.
Exploratory group analysis of resting state functional
connectivity data was carried out using dual regression
and nonparametric permutation testing (FSL randomise;
5000 permutations) with an exploratory threshold
(threshold-free cluster enhancement: P < 0.001, uncor-
rected). Individual MEP changes (before and after PAS)
were included as covariate of interest to investigate the
correlation between PAS and motor network functional
connectivity.29–32Ta
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Results
In total, 34 patients with NMDAR encephalitis and 27
healthy matched controls were recruited (Table 1). Base-
line comparisons did not reveal significant differences
between groups regarding age (t-test: P = 0.85), gender
(NMDAR encephalitis: 30 female/4 male vs. controls: 25
female/2 male), and handedness (NMDAR encephalitis:
30 right/4 left handed vs. controls: 27 right/0 left handed).
No subject reported any side effects previously considered
in TMS applications such as seizures, headache, neck
pain, or reduced concentration.
Paired associative stimulation
All data were tested for normal distribution and – if not
normally distributed – log transformed. MEP baseline val-
ues before PAS protocol did not differ significantly com-
paring both groups (unpaired, two-sided t-test: P = 0.46;
Fig. 1A and B). MEP after PAS protocol was consistently
decreased in the NMDAR encephalitis group by 10.2%
(MEP pre: 0.53  0.54 mV; MEP post: 0.48  0.89 mV),
whereas it was increased in the healthy control group by
26.1% (MEP pre: 0.63  0.42 mV; MEP post:
0.76  0.63 mV) (Fig. 1C). Testing all PAS results
together, ANOVA with independent variables for time
(MEP pre and post PAS protocol) and group (NMDAR
encephalitis vs. healthy controls) showed a significant inter-
action analysis of time and group (F1,55 = 8.35,
P = 0.0056) indicating differential PAS effects on both
groups (Fig. 1C). When expressing data as percentage of
change relative to baseline MEP, post hoc t-test confirmed
a significant difference among both groups (unpaired, two-
sided t-test: P = 0.043) (expressed as [(t2  t1)/t1] 9 100).
Figure 1. Paired associative stimulation (PAS) defines NMDAR (N-methyl-D-aspartate receptor) dysfunction in encephalitis patients and correlates
with disease severity. (A) Representative motor-evoked potential (MEP) traces of PAS assessment at baseline (left), immediately after PAS (middle)
and after 15 min (right). (B) Baseline MEP values before PAS were not different between patients with NMDAR encephalitis and healthy controls.
(C) In contrast, MEP changes before and after PAS protocol decreased in the encephalitis group, whereas they increased in the control group. (D)
Similar changes were observed in the subgroup of patients without centrally active medication.
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The same analyses were repeated in the subgroup includ-
ing only patients without centrally active medication and
with mRS > 0 (n = 11). MEP after PAS protocol showed a
decrease in the NMDAR encephalitis group of 11.93%
(MEP pre: 0.76  0.62 mV; MEP post: 0.45  0.27 mV),
whereas it increased in the healthy group by 26.1% (MEP
pre: 0.63  0.42 mV; MEP post: 0.76  0.63 mV).
ANOVA still showed a significant interaction of time and
group (F1,36 = 6.24, P = 0.0178) (Fig. 1D) indicating that
the PAS protocol had differential effects on both groups.
However, post hoc t-test revealed a nonsignificant effect
between both groups (unpaired, two-sided t-test:
P = 0.199) (expressed as [(t2  t1)/t1]9 100).
Given that mainly levetiracetam is thought to have an
effect on PAS measures (see Discussion), analyses were
repeated in a subgroup of patients without levetiracetam
medication and with mRS > 0 (n = 19). MEP after PAS
protocol showed a decrease in the NMDAR encephalitis
group of 16.80% (MEP pre: 0.52  0.51 mV; MEP
post: 0.32  0.25 mV), whereas it increased in the
healthy group by 26.1% (MEP pre: 0.63  0.42 mV;
MEP post: 0.76 0.63 mV). Similar to the whole group
analysis, ANOVA showed a significant interaction of time
and group (F1,47 = 8.90, P = 0.0047), and post hoc t-test
revealed a significant change between both groups (un-
paired, two-sided t-test: P = 0.040) (expressed as percent-
Figure 2. Characterization of transcranial magnetic stimulation (TMS) parameters in patients with NMDAR (N-methyl-D-aspartate receptor)
encephalitis. (A) Slightly increased resting motor threshold (RMT) in patients with NMDAR encephalitis versus healthy controls. (B) No difference in
RMT in patients without centrally active medication. (C) Recruitment curves of NMDAR encephalitis patients and controls. Motor-evoked potential
(MEP) values with intensity of 130%, 140%, and 150% of individual RMT. (D) Cortical silent period (CSP) with 110% and 140% in patients and
controls. No differences for short intracortical inhibition (SICI) (E) and intracortical facilitation (ICF) (F) between patients with NMDAR encephalitis
and controls.
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age of change relative to baseline MEP (%): [(t2  t1)/
t1] 9 100).
Other TMS-derived neurophysiological
assessments
Comparing patients with healthy controls (Fig. 2A), there
was a significant difference in RMT (NMDAR encephalitis:
39.65  7.95% stimulator output; controls: 34.81
 6.42%; unpaired, two-sided t-test: P = 0.015). Data for
RMT were normally distributed. Subgroup analysis of 11
patients without centrally active medication and mRS > 0
compared to controls (Fig. 2B) showed no significant dif-
ferences (NMDAR encephalitis: 36.55  6.98%; controls:
34.81  6.42%; unpaired, two-sided t-test: P = 0.45), sug-
gesting that the higher RMT in patients may be related to
functional impairment in NMDAR encephalitis or the
effect of medication.
To exclude effects of interindividual RMT (which is
highly variable also in healthy subjects), MEP measure-
ments were routinely standardized at the intensity of
130% of individual RMT which is the well-accepted gold
standard. MEP at intensities of 130% and 150% of RMT
were compared between groups revealing no significant
differences (unpaired, two-sided t-test: 130%: P = 0.146;
150%: P = 0.1941). Analyzing the nonmedication sub-
group, t-tests were also not significantly different between
groups (130%: P = 0.776; 150%: P = 0.068). In contrast,
MEP with 140% (which is part of the RC analysis)
showed a significant difference between NMDAR
encephalitis patients and healthy controls (unpaired, two-
sided t-test: P = 0.0073), whereas subgroup analyses
revealed no significant differences (P = 0.1226). Similarly,
the RC (t-test: 150%/130%: P = 0.974; 140%/130%:
P = 0.6432; 150%/140%: P = 0.591; Fig. 2C), the CSP
with 110% and 140% intensity (110% t-test: P = 0.351;
140% t-test: P = 0.2336; Fig. 2D), and the paired-pulse
parameters of SICI and ICF (expressed as: ICF/MEP;
SICI/MEP; t-test: SICI: P = 0.192; ICF: P = 0.394; Fig. 2E
and F) were not different between patients and controls.
Correlation analyses
PAS and mRS
Correlation analysis was performed in order to detect an
association of mRS and changes of MEP after PAS in
patients with NMDAR encephalitis and controls. Data
showed a clear association of better functional scales with
PAS changes (P = 0.0031, Pearson’s correlation,
r = 0.41; Fig. 3A). In contrast, there was no correlation
between PAS changes and disease duration, arguing
against improvement of PAS measurement simply due to
longer duration from the acute phase of the encephalitis
(P = 0.9464, Pearson’s correlation, r = 0.01; Fig. 3B).
PAS and resting state functional connectivity
Higher functional connectivity within the motor network
was correlated with higher PAS-induced plasticity in
NMDAR encephalitis patients (P < 0.001, uncorrected),
that is, higher functional connectivity between the motor
Figure 3. (A) Paired associative stimulation (PAS) changes correlate
with disease severity as measured with the modified Rankin Scale
(mRS). (B) In contrast, PAS changes did not correlate with the
duration of disease. (C) Correlation of PAS-induced plasticity with
motor network functional connectivity. Resting state functional
connectivity of the motor network with bilateral precentral gyrus
correlated positively with PAS-induced plasticity in NMDAR (N-methyl-
D-aspartate receptor) encephalitis patients.
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network as a whole and bilateral precentral gyrus regions
was associated with higher PAS-induced plasticity (Fig. 3C).
Follow-up analyses
Of the 34 enrolled patients with NMDAR encephalitis,
six were available for follow-up analysis (Table 2). Five
patients showed clinical improvement measured with the
mRS, all of these also showed improvement in the PAS
protocol suggesting that TMS could potentially be help-
ful in the monitoring of clinical improvement. One
patient was clinically unchanged at follow-up after a
prolonged clinical relapse; here no PAS improvement
was detectable.
Discussion
The present study demonstrated significant differences in
PAS-induced plasticity in patients with NMDAR
encephalitis compared to healthy controls, namely
decreases in patients and increases in controls. Given that
PAS-induced plasticity is dependent on NMDAR func-
tion, these findings for the first time provide in vivo neu-
rophysiological evidence of malfunctioning of NMDAR
capacity in a large sample of patients harboring patho-
genic antibodies against the NMDAR. Moreover, brain
dysfunction as indexed by PAS results were significantly
correlated with disease severity and motor network func-
tional connectivity. Follow-up assessments demonstrated
parallel improvement of PAS-induced plasticity and mRS.
No differences emerged between groups for markers of
GABA(A/B)ergic function indicating specificity for dysfunc-
tion in glutamatergic-based LTP-like plasticity.
To the best of our knowledge, only one case report has
documented TMS-derived neurophysiological measure-
ments in the acute phase of a woman with NMDAR
encephalitis,33 reporting normal MEP amplitudes and
latencies, as well as intact corticospinal tracts, consistent
with our findings. Initially, the protocol of sensory afferent
facilitation (protocol of a conditioning electrical stimulus
applied to a peripheral nerve followed by a TMS pulse to
the contralateral M1 which typically enhances MEP)
showed an exaggerated response, but improved and nor-
malized after patient’s health condition increased and was
stabilized while sensory afferent inhibition (protocol of an
electrical stimulus applied to a peripheral nerve followed by
a TMS pulse which typically suppresses MEP34) remained
absent both times. This is consistent with our follow-up
data showing parallel improvement of PAS and mRS.
Resting state functional MRI has been shown to reveal
characteristic alterations of functional connectivity in
NMDAR encephalitis patients despite normal routine
MRI.29 Specifically, it was shown that patients have
reduced functional connectivity of the hippocampus with
the default mode network that correlated with individual
memory performance. Here, we found that motor net-
work connectivity predicted individual PAS response in
patients. This observation indicates that functional con-
nectivity alterations might be even more widespread and
include the motor network. Moreover, these findings may
provide a link between electrophysiological and imaging
markers of NMDAR dysfunction in encephalitis patients
given that combination of these two complementary tools
will advance studies of brain connectivity, although the
exact interaction needs to be addressed in further
studies.35
We further provide new safety data on single- and
paired-pulse TMS. TMS application included patients suf-
fering from encephalitis-related seizures in the past with
the last seizure >6 months before. Antiepileptic drugs
were not changed for the study. No patient experienced a
seizure. Based on these data it seems ethically justified in
prospective studies to also perform TMS in patients with
acute NMDAR encephalitis as the probability of triggering
seizures with single- and paired-pulse TMS seems to be
extremely low. Literature reviews support the notion that
single- and paired-pulse TMS are safe, most likely also in
patients with epilepsy.36 Future studies should therefore
Table 2. Follow-up data.
Patient ID
Disease months
Visit 1/2
mRS
Visit 1/2
Antibody titer
PAS (% change)
Visit 1/2
Change of medication
Visit 1 ? 2
Serum
Visit 1/2
CSF
Visit 1/2
4 14/38 3/2 32/100 1/n.d. 57.63/13.95 (↑) No
7 42/66 2/1 0/0 0/0 6.47/+1.89 (↑) LEV ? Escitalopram
10 46/61 1/1 32/0 1/0 8.25/1.56 (↑) No
15 57/74 1/0 10/32 32/n.d. 58.71/+101.28 (↑) No
17 5/13 2/1 100/100 10/n.d. 39.61/18.49 (↑) VAL ? LTG
21 8/12 3/3 320/100 32/32 35.01/43.88 (↓) Quetiapin ? No
mRS, modified Rankin Scale; CSF, cerebrospinal fluid; PAS, paired associative stimulation; n.d., not determined; LTG, lamotrigin; VPA, valproate;
LEV, levetiracetam.
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include patients in the acute phase of NMDAR encephali-
tis as this will likely result in further clues on the pre-
dictability of clinical progression/remission, relapses,
therapy responses, and prognosis.33
A potential confounding factor for TMS is the use of
central nervous system (CNS)-active medication. Previous
studies showed an effect mainly for levetiracetam on the
PAS protocol, whereas most drugs did not affect this
measurement, such as tiagabine, diazepam, lamotrigine,
piracetam, gabapentin, and topiramate.17 Reanalysis of
our data using both a subgroup of patients lacking leve-
tiracetam and patients lacking all CNS-active medications
lead to equal results confirming the significant PAS differ-
ences between NMDAR encephalitis patients and controls.
When comparing all encephalitis patients with controls,
we found significant differences in RMT which was not
detectable in the subgroup without centrally active medi-
cation (including all drugs such as tiagabine, diazepam,
lamotrigine, piracetam, gabapentin, topiramate, and leve-
tiracetam). Even though there is somewhat conflicting
data whether levetiracetam has large or subtle effects on
single-pulse TMS parameters,37–39 we conclude that the
observed differences in RMT might partially depend on
medication, while the observed PAS effect is most likely
related to receptor changes attributable to NMDAR
encephalitis. However, it is also possible that the sub-
group without medication was too small to detect differ-
ences (n = 11), and larger patient sizes are needed to
confirm the influence of the medication. Finally, it is pos-
sible that the subgroup required less medication because
of more advanced clinical remission, even though mRS
was not better in the subgroup. Another limitation is the
fact that only six patients were available for follow-up
analyses. Since the prevalence of NMDAR encephalitis is
relatively low, follow-up studies with a bigger sample size
would need several more years. However, the data of six
patients suggest that PAS and mRS changed in the same
way regarding disease improvement or deterioration. ICF
did not show a significant difference among groups. One
might have expected impaired ICF in NMDAR encephali-
tis patients since ICF is known to be (at least partially)
mediated through NMDAR. However, ICF is not solely
mediated by NMDAR, but also by GABAA receptors as
indicated in studies with benzodiazepines4,40,41 as well as
by non-NMDA glutamate receptors.4,42 In addition, keta-
mine, an NMDAR antagonist, showed no effects on
ICF.16 PAS is known to be predominantly mediated via
NMDAR, however, also other neurotransmitters with dif-
ferent dominance are likely involved. Despite contribution
of NMDAR currents in both ICF and PAS, they are inde-
pendent TMS parameters with different underlying mech-
anisms, which explain why only one of these two
neurophysiological measurements can be altered.
It is an intriguing question as to whether TMS might
not only be useful for early determination of disease
severity and follow-up monitoring in NMDAR
encephalitis, but also whether therapeutic application can
improve hippocampal function and synaptic plasticity.
There is evidence from animal models that rTMS may
increase the mRNA and protein expression of
NMDAR.43 A human study confirmed that after-effects
of rTMS (theta burst stimulation) are linked to the
function of the NMDAR.44 Moreover, animal and behav-
ioral studies45–49 provide compelling evidence that rTMS
alters synaptic plasticity of hippocampal areas. Thus,
rTMS may be used in order to improve hippocampal
function and increase neuronal NMDAR expression.
Along these lines, prospective studies should evaluate its
potential for therapeutic application in patients with
NMDAR encephalitis.
Taken together, we show that (1) there was a signifi-
cant difference in PAS between NMDAR encephalitis
patients and healthy controls, (2) other TMS-derived neu-
rophysiological parameters which are not mediated
through NMDAR were not altered, (3) neurophysiological
parameters depend on the disease state, and (4) were sig-
nificantly correlated with already established markers of
disease activity such as mRS and resting state functional
connectivity. Thus, measurement of PAS-induced plastic-
ity may help to detect subtle NMDAR dysfunction and
disease severity in NMDAR encephalitis. It might even
serve as a sensitive, widely available and noninvasive
“neurophysiological biomarker” to support diagnostic and
therapeutic decisions and to monitor therapy response in
the future. In six available patients, follow-up analyses
demonstrated parallel improvement of PAS changes and
mRS. If the findings are confirmed in larger follow-up
cohorts, TMS will be an objective way to monitor the dis-
ease course, to identify relapses, and to control therapy
responses.
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Additional Supporting Information may be found in the
online version of this article:
Table S1. Checklist for assessing the methodological qual-
ity of TMS reporting.
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